WESTBOROUGH, Mass., April 5 /PRNewswire/ -- IBC Life Sciences announced the keynote presenters for the 12th Annual Drug Discovery & Development of Innovative Therapeutics World Congress would be 2006 Nobel Prize Winner in Physiology or Medicine, Craig C. Mello, Ph.D., Howard Hughes Medical Institute Investigator, The Blais University Chair in Molecular Medicine for the University of Massachusetts Medical School and Frank L. Douglas, M.D., Ph.D, Executive Director at MIT Center for Biomedical Innovation. This event will take place in Boston, Massachusetts on August 6-9, 2007.
Dr. Mello's address, "RNAi: From Mechanism to Medicine," will discuss how RNAi has provided a powerful research tool for experimentally knocking out the expression of specific genes and how it has opened a completely new and totally unanticipated window on developmental gene regulation. He will also discuss how RNAi is now showing promise in the clinic as new class of gene- specific therapeutics.
Dr. Douglas's address, "The Challenge of Innovation: Transforming the Industry Today and Tomorrow" will look at the challenges facing the drug industry and how to innovate in a "flat" world. His presentation will also highlight how the MIT Center of Biomedical Innovation is building a new model for a better future.
The Drug Discovery & Development of Innovative Therapeutics (DDT) World Congress expects more than 3,000 pharmaceutical, biotechnology, government and academic researchers, executives and technology providers to participate. The event focuses on scientific innovations, new approaches and business strategies that are helping companies to accelerate movement of compounds into the clinic. This year's program includes:
3 Pre-Conference Summits -- Capitalizing on the Thriving Antibody Therapeutics Market -- Informatics throughout the Discovery & Development Value Chain -- Licensing & M&As - Global Trends in Pharma-Biotech Partnering 4 Therapeutic Drug Discovery and development Conference Tracks -- Cancer -- Metabolic Disease -- Inflammatory Disease -- CNS 6 Focus Area Sessions
-- Getting into the Clinic in a Cost-Effective Way: Small Company Approaches
-- Exploratory IND and Phase 0 - Strategies for Candidate Prioritization and Getting to First-in-Human
-- Executive Insights on R&D Challenges and Strategies to Stay Ahead -- Translating Stem Cell Research into a Viable Business or Product -- Early Development Strategies in Phase 1 and 2 -- Transforming Technologies for Scientific Advances 3 Post-Conference Workshops -- LifeCycle Management and Drug Repositioning Strategies -- RNAi Technologies and Therapeutics: From Basic Research to Products -- Novel In Vivo Disease Models for Earlier Safety and Efficacy Prediction
In addition, DDT provides one of the largest exhibitions of drug discovery and development related products, technologies and services in the world.
Complete details on this event can be found at www.drugdisc.com or to receive a press pass or arrange an interview with a speaker, email Dawn O'Connor at doconnor@ibcusa.com.
About IBC Life Sciences
IBC Life Sciences is the worldwide leader in scientific, technological and business conferences and courses for the life science industry. To develop its programs, IBC actively researches the advancements, technologies and trends impacting and driving the race for new drugs and therapies. No other organization can make claim to the breadth and quality that IBC Life Sciences delivers in each event giving the company recognition around the globe for quality, service and value. For more information, visit: http://www.IBCLifeSciences.com.
Contact: Dawn O'Connor IBC Life Sciences 508 - 614 - 1679 doconnor@ibcusa.com
IBC Life SciencesCONTACT: Dawn O'Connor of IBC Life Sciences, +1-508-614-1679, ordoconnor@ibcusa.com
